Brief: Beyondspring - Expect To File NDA For Cin To U.S. FDA By End Of Year
03/09/2020 12:51
Sept 3 (Reuters) - Beyondspring Inc BYSI.O :
* BEYONDSPRING INC - EXPECT TO FILE NDA FOR CIN,
PLINABULIN'S
FIRST INDICATION, TO U.S. FDA BY END OF YEAR
* BEYONDSPRING - NET LOSS ATTRIBUTABLE TO CO WAS $12.8
MILLION FOR
QUARTER ENDED JUNE 30, 2020 VERSUS $7.4 MILLION
* BEYONDSPRING - AS OF JUNE 30, 2020, HAD A CASH AND CASH
EQUIVALENTS OF $38.1 MILLION
* BEYONDSPRING - BELIEVES HAS SUFFICIENT CASH TO SUPPORT
CLINICAL
TRIALS & SUBMIT NDA IN U.S. FOR PLINABULIN FOR CIN INDICATION
Source text for Eikon: ID:nGNX6pqdPR
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value